ClinicalTrials.gg
RecruitingNCT06578676Updated Aug 29, 2024

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

A Phase 1 interventional study of Empagliflozin 25 MG and Ezetimibe/Rosuvastatin 10/10mg in Type 2 Diabetes and Dyslipidemias, sponsored by Hyundai Pharm. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Hyundai Pharm · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
80th of 130
56 · median 79
Started
2024
with 6 others
Phase 1
24 of 130
5 open now
Primary completion
2024-09
later than 2 of 18 live
Registered
106th of 130
by date

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 80th largest by planned enrollment, is one of 7 that started in 2024, is one of 24 in phase 1, reaches primary completion later than 2 of the 18 other live ones, and was the 106th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.

Read the detailed description

This trial is a phase 1 study to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg of Ezetimibe/Rosuvastatin in steady state in healthy volunteers.

This is open-label, multiple-dose, two-arm, two-period and fixed-sequence design.

In Arm A, 18 subjects will be assigned. The subjects take 25mg of empagliflozin for 5days(Period 1). After 7days of washout period, the subjects take 10/10mg of Ezetimibe/Rosuvastatin for 2days and take co-administrated 25mg of Empagliflozin and 10/10mg of Ezetimibe/Rosuvastatin for 5days.

In Arm B, 38 subjects will be assigned. The subjects take 10/10mg of Ezetimibe/Rosuvastatin for 7days(Period 1). After 14days of washout period, the subjects take 25mg of empagliflozin for 2days and take co-administrated 25mg of Empagliflozin and 10/10mg of Ezetimibe/Rosuvastatin for 5days.

03

Conditions studied

  • Type 2 Diabetes
  • Dyslipidemias
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age: 19 and over , healthy volunteer
  • (BMI): 18.5≤BMI≤29.9 kg/m²

Exclusion criteria

Exclusion Criteria:

  • Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal
  • findings(e.g. blood pressure, (ECG); physical and gynecological examination, laboratory examination)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Empagliflozin 25mg

    * Period 1: Empagliflozin (QD, 5d) * wash-out: 7d * Period 2: Ezetimibe/Rosuvastatin (QD, 2d) and Empagliflozin and Ezetimibe/Rosuvastatin (QD, 5d)

    Drug: Empagliflozin 25 MG · Drug: Ezetimibe/Rosuvastatin 10/10mg · Drug: Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg

  • Experimental
    Rosuvastatin/Ezetimibe 10/10mg

    * Period 1: Ezetimibe/Rosuvastatin (QD, 7d) * wash-out: 14d * Period 2: Ezetimibe/Rosuvastatin (QD, 2d) and Empagliflozin and Ezetimibe/Rosuvastatin (QD, 5d)

    Drug: Ezetimibe/Rosuvastatin 10/10mg · Drug: Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg

Interventions

  • PO, QD

  • DrugEzetimibe/Rosuvastatin 10/10mg

    PO, QD

  • DrugEmpagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg

    PO, QD

06

What researchers measure

Primary outcomes

  1. Cmax,ss of Empagliflozin, Total Ezetimibe and Rosuvastatin

    Cmax,ss of Empagliflozin, Total Ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48hours of after administration

  2. AUCtau,ss of Empagliflozin, Total Ezetimibe and Rosuvastatin

    AUCtau,ss of Empagliflozin, Total Ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

Secondary outcomes

  1. Vdss/F of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Vdss/F of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

  2. Cmax,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Cmax,ss, AUCtau,ss, AUCinf,ss, Tmax,ss, Cmin,ss, t1/2,ss, CLss/F, Vdss/F of Free ezetimibe

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

  3. AUCtau,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    AUCtau,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

  4. AUCinf,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    AUCinf,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

  5. Tmax,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Tmax,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

  6. Cmin,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Cmin,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

  7. t1/2,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    t1/2,ss of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

  8. CLss/F of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    CLss/F of Free ezetimibe, Empagliflozin, Total ezetimibe and Rosuvastatin

    Time frame: 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72hours of after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Sep 2024, 2 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2024
First posted
Aug 29, 2024
StartActual
Jun 20, 2024
Primary completionEst.
Sep 2, 2024
CompletionEst.
Nov 30, 2024
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06578676
Lead sponsor
Hyundai Pharm
Collaborators
Kyungpook National University Hospital
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Jun 20, 2024
Primary completion
Sep 2, 2024 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Aug 29, 2024

Study contacts

Young-Ran Yoon, PhD
Contact
yry@knu.ac.kr
+82 53-200-6351

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion